Beigene Ltd (BGNE)

traders view logo Charts by TradingView

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

Beigene Ltd (BGNE) Profile

Beigene Ltd (ADRs) (BGNE.xnas) is a biotechnology company headquartered in Beijing, China. Beigene specialises in the development of drugs for cancer treatment. Its products include tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton’s tyrosine kinase inhibitor, which became the 1st cancer drug developed in China to gain approval from the U.S Food and Drug Administration. Beigene has offices in China, Australia, the United States and Europe and employs approximately 3,500 people worldwide. Beigene Ltd stock is listed on the NASDAQ and had a market capitalisation of $26.59B (USD) as of January 2022 and $1.11B (USD) in 2021 yearly revenues. At the end of 2021, the company announced an option, collaboration and licence agreement with Novartis Pharma AG to develop, manufacture and commercialise Beigene’s investigational TIGIT inhibitor ociperlimab in Europe, North America, and Japan. Additionally, both companies entered into an agreement granting Beigene rights to market, promote and detail five approved Novartis oncology products across designated regions of China. The European Commission (EC) approved Beigene’s drug BRUKINSA to treat adult patients with Waldenstrom’s macroglobulinemia (WM).

Holding cost
Long
-5%
Short
-2.5%
Trading hours in US Eastern Time
Fri
16:30-23:00
Mon
16:30-23:00
Tue
16:30-23:00
Wed
16:30-23:00
Thu
16:30-23:00
Sun
Closed
Sat
Closed

Share CFD Trading FAQ

Each investor owning shares of a company is also owning fragments of the company. A quite simple way to explain what a stock is is basically when a company divides itself into several shares and then it makes a part of these equities available to the public, at a price. Each investor owning shares of a company is owning fragments of the company.

While shares represent units of ownership within a company Contracts for Difference (CFDs) allow traders to speculate on the future share price fluctuations of an underlying asset. Thus when trading CFDs traders do not physically own the underlying asset. CFDs are available for a range of underlying assets, such as shares, commodities, and foreign exchange, and indices.

Why Trade Beigene Ltd (ADRs) (BGNE.xnas) with FP Markets? An Australian-regulated forex & CFD broker
go long or short
Go Long or Short

Increase your ability to profit in
all market conditions
Leverage options up to 20:1

direct market access
Direct Market Access (DMA) Execution

Real-time, transparent share prices
Control, Functionality and deep liquidity
Full Market depth & see your orders in the queue

advanced platforms
Advanced Platforms
& Technology

MT4, MT5, Webtrader & Iress with
superior client portal

24/5 Multilingual customer support
24/5 Multilingual
Customer Support

Award winning support &
personal account managers

global exposure
Global Exposure

Low margins and competitive commission
+10,000 products on global stocks
across 4 continents

earn dividends
Earn Dividends

On long positions
No ownership of physical
shares necessary

Start Trading
in Minutes

bullet Access 10,000+ financial instruments
bullet Auto open & close positions
bullet News & economic calendar
bullet Technical indicators & charts
bullet Many more tools included

By supplying your email you agree to FP Markets privacy policy and receive future marketing materials from FP Markets. You can unsubscribe at any time.




Source - database | Page ID - 6467

Get instant Updates in Telegram